Delivery Order SPE2DB22D3010-SPE2DB25FP3JX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,062.43 to AmerisourceBergen Drug Corp for the supply of XYOSTED 50 mg/0.5 ml auto-injector units. The contract is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, awarded on August 21, 2025, with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a $1,751.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $1,365.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pharmaceutical supplies. This non-set-aside award, issued on August 25, 2025, with completion targeted for August 26, 2025, represents a single delivery transaction under AmerisourceBergen's existing DLA contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $2,672.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units, with performance conducted at the company's Corporate Office location in Conshohocken, Pennsylvania. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and utilized no set-aside designation, indicating competitive award selection. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,358.05 to AmerisourceBergen Drug Corp for XYOSTED 50 MG/0.5 ML auto-injectors (0.5 ML) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was not set-aside and competitively awarded. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with a completion date of July 31, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order valued at $1,086.44 to AmerisourceBergen Drug Corp for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3JXDelivery Order
The Defense Logistics Agency (DLA) awarded a $2,935.72 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. This delivery order for XYOSTED, a testosterone replacement therapy auto-injector, falls within the company's broader portfolio of specialty pharmaceuticals and medical devices delivered through the DLA's global pharmaceutical support vehicle. The underlying IDC enables AmerisourceBergen to serve military healthcare customers including the Defense Health Agency and U.S. Coast Guard across multiple therapeutic domains through flexible delivery order mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 9/4/25 |